Clinical Trial

Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated August 25, 2023 (before its estimated July 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
To investigate the clinical efficacy and safety of envollizumab combined with fruquintinib and SOX versus SOX in conversion therapy for patients with Her-2 negative, unresectable locally advanced gastric cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-06-13.
Trial Details
NCT Number NCT05914610
Lead Sponsor Fujian Medical University
Conditions Gastric Cancer
Enrollment 100 participants
Start Date 2023-09-01
Primary Completion 2025-07-30 (estimated)
Study Completion 2028-07-30 (estimated)
Updated on ClinicalTrials.gov 2023-08-25